NOX1/NADPH oxidase is involved in the LPS-induced exacerbation of collagen-induced arthritis.


Journal

Journal of pharmacological sciences
ISSN: 1347-8648
Titre abrégé: J Pharmacol Sci
Pays: Japan
ID NLM: 101167001

Informations de publication

Date de publication:
Jun 2021
Historique:
received: 02 10 2020
revised: 19 01 2021
accepted: 25 01 2021
entrez: 4 5 2021
pubmed: 5 5 2021
medline: 21 10 2021
Statut: ppublish

Résumé

We investigate as yet an unidentified role of NOX1, a non-phagocytic isoform of the superoxide-generating NADPH oxidase, in immune responses using Nox1-knockout mice (Nox1-KO). The transcripts of NOX1 was expressed in lymphoid tissues, including the spleen, thymus, bone marrow, and inguinal lymphoid nodes. When antibody production after ovalbumin (OVA) immunization was examined, no significant differences were observed in serum anti-OVA IgG levels between wild-type mice (WT) and Nox1-KO. In the experimental asthma, the infiltration of eosinophils and the Th2 cytokine response after the induction of asthma with OVA were similar between the two genotypes. However, the severity and incidence of experimental collagen-induced arthritis (CIA) following the administration of a low dose of endotoxin (LPS) were significantly lower in Nox1-KO. While neither serum levels of autoantibodies nor in vitro cytokine responses were affected by Nox1 deficiency, NOX1 mRNA levels in the spleen significantly increased after the LPS challenge. Among the spleen cells, remarkable LPS-induced upregulation of NOX1 was demonstrated in both CD11b

Identifiants

pubmed: 33941325
pii: S1347-8613(21)00010-4
doi: 10.1016/j.jphs.2021.01.009
pii:
doi:

Substances chimiques

Endotoxins 0
RNA, Messenger 0
Collagen 9007-34-5
NADPH Oxidase 1 EC 1.6.3.-
NOX1 protein, mouse EC 1.6.3.-

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

88-97

Informations de copyright

Copyright © 2021 The Authors. Production and hosting by Elsevier B.V. All rights reserved.

Déclaration de conflit d'intérêts

Declaration of competing interest C. Y.-N. is the cofounder of a startup company developing NOX inhibitors.

Auteurs

Misaki Matsumoto (M)

Department of Pharmacology, Kyoto Prefectural University of Medicine, Kyoto, Japan. Electronic address: m-matsu@koto.kpu-m.ac.jp.

Junjie Liu (J)

Department of Pharmacology, Kyoto Prefectural University of Medicine, Kyoto, Japan.

Kazumi Iwata (K)

Department of Pharmacology, Kyoto Prefectural University of Medicine, Kyoto, Japan.

Masakazu Ibi (M)

Department of Pharmacology, Kyoto Prefectural University of Medicine, Kyoto, Japan.

Nozomi Asaoka (N)

Department of Pharmacology, Kyoto Prefectural University of Medicine, Kyoto, Japan.

Xueqing Zhang (X)

Department of Pharmacology, Kyoto Prefectural University of Medicine, Kyoto, Japan.

Masato Katsuyama (M)

Radioisotope Center, Kyoto Prefectural University of Medicine, Kyoto, Japan.

Masaya Matsuda (M)

Laboratory of Immunopharmacology, Faculty of Pharmaceutical Sciences, Setsunan University, Osaka, Japan.

Takeshi Nabe (T)

Laboratory of Immunopharmacology, Faculty of Pharmaceutical Sciences, Setsunan University, Osaka, Japan.

Katrin Schröder (K)

Institute for Cardiovascular Physiology, Goethe-University, Frankfurt, Germany.

Chihiro Yabe-Nishimura (C)

Department of Pharmacology, Kyoto Prefectural University of Medicine, Kyoto, Japan.

Articles similaires

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male
Humans Meals Time Factors Female Adult

Classifications MeSH